Literature DB >> 29552211

MicroRNA-126 affects ovarian cancer cell differentiation and invasion by modulating expression of vascular endothelial growth factor.

Jianqiao Luo1,2, Caidan Zhu2, Hongya Wang2, Li Yu2, Jianwei Zhou2.   

Abstract

Primary ovarian cancer is the main cause of gynecological cancer-associated mortality. However, the mechanism behind the spread of ovarian cancer requires elucidation. The present study aimed to investigate the effects of microRNA-126 (miR-126) on differentiation and invasion, and its mechanism in primary ovarian cancer. Ovarian cancer SKOV3 cells transfected with LV3-has-miR-126 mimics and LV3-has-miR-126 inhibitor were produced; it was revealedthatLV-miR-126 mimics could induce cell cycle arrest at G1 phase, suppress cell invasion through Matrigel-coated membranes and downregulate the expression of vascular endothelial growth factor (VEGF). Furthermore, LV-has-miR-126 inhibitor-transfected cells could increase the number of cells in S phase, induce cell invasion and upregulate the expression of VEGF. The present study, to the best of our knowledge, is the first to report that miR-126 may serve tumor suppressor roles by inducing G1 cell cycle arrest and suppressing invasion in ovarian cancer cells, at least in part by targeting VEGF expression.

Entities:  

Keywords:  cell cycle; invasion; microRNA-126; ovarian cancer; vascular endothelial growth factor

Year:  2018        PMID: 29552211      PMCID: PMC5840569          DOI: 10.3892/ol.2018.8025

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  39 in total

1.  Epidemiology of ovarian cancer: a status report.

Authors:  Elizabeth R Bertone-Johnson
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

Review 2.  Clinical applications of VEGF-trap (aflibercept) in cancer treatment.

Authors:  Li-Song Teng; Ke-Tao Jin; Kui-Feng He; Jing Zhang; Hao-Hao Wang; Jiang Cao
Journal:  J Chin Med Assoc       Date:  2010-09       Impact factor: 2.743

3.  MicroRNA library-based functional screening identified miR-137 as a suppresser of gastric cancer cell proliferation.

Authors:  Xiushan Zheng; Jiaqiang Dong; Taiqian Gong; Zhiyong Zhang; Ying Wang; Yunming Li; Yulong Shang; Kai Li; Gui Ren; Bin Feng; Juntang Li; Qifei Tian; Shanhong Tang; Li Sun; Mengbin Li; Hongwei Zhang; Daiming Fan
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-24       Impact factor: 4.553

4.  microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3 cells.

Authors:  Ping Luo; Jing Fei; Jianwei Zhou; Weijiang Zhang
Journal:  Oncol Lett       Date:  2015-03-03       Impact factor: 2.967

5.  miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5.

Authors:  Edit Miko; Zoltán Margitai; Zsolt Czimmerer; Ildikó Várkonyi; Balázs Dezso; Arpád Lányi; Zsolt Bacsó; Beáta Scholtz
Journal:  FEBS Lett       Date:  2011-03-23       Impact factor: 4.124

6.  Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability.

Authors:  Michael Bieri; Melinda Oroszlan; Anikò Farkas; Nathalie Ligeti; Jürg Bieri; Paul Mohacsi
Journal:  Int J Biochem Cell Biol       Date:  2009-07-03       Impact factor: 5.085

7.  High circulating VEGF level predicts poor overall survival in lung cancer.

Authors:  Pingping Hu; Weidong Liu; Liguang Wang; Miaomiao Yang; Jiajun Du
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-04       Impact factor: 4.553

8.  Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells.

Authors:  Alla Musiyenko; Vira Bitko; Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2008-01-12       Impact factor: 4.599

9.  Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase.

Authors:  Yoshiko Awazu; Akio Mizutani; Yoshinori Nagase; Shuntarou Tsuchiya; Kazuhide Nakamura; Yuichi Kakoi; Osamu Kitahara; Toshiyuki Takeuchi; Seiji Yamasaki; Naoki Miyamoto; Hidehisa Iwata; Hiroshi Miki; Shinichi Imamura; Akira Hori
Journal:  Cancer Sci       Date:  2013-02-18       Impact factor: 6.716

10.  let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non--small--cell lung cancer.

Authors:  Edin Jusufović; Matija Rijavec; Dragan Keser; Peter Korošec; Eva Sodja; Ermina Iljazović; Zorica Radojević; Mitja Košnik
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

View more
  4 in total

1.  Tumor microRNA-126 controls cell viability and associates with poor survival in patients with esophageal adenocarcinoma.

Authors:  Ela Toxopeus; N Lynam-Lennon; K Biermann; G Dickens; P E de Ruiter; Jjb van Lanschot; J V Reynolds; Bpl Wijnhoven; J O'Sullivan; Ljw van der Laan
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-07

2.  MicroRNA-126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial-to-mesenchymal transition and ERK/MAPK signaling pathway.

Authors:  Yuhua Zhang; Xiaobo Qin; Juan Jiang; Wenjie Zhao
Journal:  Oncol Lett       Date:  2020-05-29       Impact factor: 2.967

Review 3.  Mechanisms of Vasculogenic Mimicry in Ovarian Cancer.

Authors:  Lízbeth Ayala-Domínguez; Leslie Olmedo-Nieva; J Omar Muñoz-Bello; Adriana Contreras-Paredes; Joaquín Manzo-Merino; Imelda Martínez-Ramírez; Marcela Lizano
Journal:  Front Oncol       Date:  2019-09-27       Impact factor: 6.244

4.  MicroRNA-210 targets FBXO31 to inhibit tumor progression and regulates the Wnt/β-catenin signaling pathway and EMT in esophageal squamous cell carcinoma.

Authors:  Jing Meng; Chao Zhang; Tongquan Zhao; Guangwen Shi; Jingjing Zhao; Zhaoxia Lin
Journal:  Thorac Cancer       Date:  2021-02-03       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.